Intravitreal Bevacizumab for Choroidal Neovascularization Secondary to Best Vitelliform Macular Dystrophy in a 6-Year-Old Child

2012 ◽  
Vol 22 (4) ◽  
pp. 677-679 ◽  
Author(s):  
Jay Chhablani ◽  
Subhadra Jalali
Keyword(s):  
Choroidal Neovascularization ◽  
Intravitreal Bevacizumab ◽  
Macular Dystrophy ◽  
Vitelliform Macular Dystrophy ◽  
Best Vitelliform Macular Dystrophy

Intravitreal bevacizumab treatment for exudative choroidal neovascularisation in best vitelliform macular dystrophy

2021 ◽  
pp. 112067212110576
Author(s):  
Martina Jarc-Vidmar ◽  
Rok Sega ◽  
Polona Jaki-Mekjavic
Keyword(s):  
Visual Acuity ◽  
Paediatric Patient ◽  
Case Series ◽  
Intravitreal Bevacizumab ◽  
Choroidal Neovascularisation ◽  
Macular Dystrophy ◽  
Central Scar ◽  
Vitelliform Macular Dystrophy ◽  
Best Vitelliform Macular Dystrophy ◽  
Bevacizumab Treatment

Purpose To describe results of intravitreal bevacizumab treatment of the secondary choroidal neovascularisation in Best vitelliform macular dystrophy in an adult and paediatric patient, and present the management of three asymptomatic patients with confirmed BEST1 gene mutation. Case series description Five patients from the same family with the Best vitelliform macular dystrophy are presented. In two patients (aged 63 and 4 years) secondary choroidal neovascularisation caused a rapid decline in visual acuity. In the adult patient with advanced Best vitelliform macular dystrophy, visual acuity did not improve despite eight intravitreal bevacizumab injections to the right eye. The formation of a central scar and rapid reoccurrence of choroidal neovascularisation three months after completing the initial treatment affected the outcome. As for the paediatric patient with bilateral choroidal neovascularisation in the vitelliform stage of Best vitelliform macular dystrophy, a complete recovery of visual acuity was observed after two (left eye) and three (right eye) bevacizumab injections, with adjunctive amblyopia treatment. The other three patients with an abnormal electrooculogram reported no visual problems during more than 10 years of follow-up. Minimal changes were seen on optical coherence tomography in the youngest patient. Conclusions Intravitreal bevacizumab seems to be an effective treatment for exudative choroidal neovascularisation in the vitelliform stage of Best vitelliform macular dystrophy; however, it may not be beneficial in the advanced stages of Best vitelliform macular dystrophy. It is important to regularly screen all family members with an abnormal electrooculogram and confirmed mutation for vitelliform changes and choroidal neovascularisation from an early age. The decision for anti-vascular endothelial growth factor treatment should be made on a case-to-case basis as complications may arise.

scholarly journals Intra-Vitreous Injections of Bevacizumab in Choroidal Neovascularization Complicating Best Vitelliform Macular Dystrophy: Case Report of a Child

2021 ◽  
Vol 8 (7) ◽  
Author(s):  
Elkhoyaali A ◽  
◽  
Jeddou I ◽  
Zerrouk R ◽  
Khanaouchi N ◽  
...  
Keyword(s):  
Choroidal Neovascularization ◽  
Serous Retinal Detachment ◽  
Retinal Hemorrhage ◽  
Macular Dystrophy ◽  
Vitelliform Macular Dystrophy ◽  
Best Vitelliform Macular Dystrophy ◽  
Sudden Decrease ◽  
Best Disease

A 15-year-old child followed for Best vitelliform macular dystrophy presented to the clinic with an abrupt visual impairment of his left eye. Fundus examination showed bilateral vitelliform lesions, with serous retinal detachment and adjacent retinal hemorrhage in the left eye. Fluorescein angiography and optical coherence tomography confirmed the diagnosis of type-2 choroidal neovascularization complicating the Best disease. The juxtafoveal location of the choroidal neovascularization prompted us to realize monthly intra-vitreous injections of bevacizumab. After the fourth injection, we observed visual and anatomical improvement that remained stable after a 12-month follow-up. It’s important to look for complications in front of a sudden decrease in visual acuity in Best disease.

PREFERENTIAL HYPERACUITY PERIMETER IN BEST VITELLIFORM MACULAR DYSTROPHY

Retina ◽  
2011 ◽  
Vol 31 (5) ◽  
pp. 959-966 ◽  
Author(s):  
Giuseppe Querques ◽  
Karim Atmani ◽  
Rislie Bouzitou-Mfoumou ◽  
Nicolas Leveziel ◽  
Nathalie Massamba ◽  
...  
Keyword(s):  
Macular Dystrophy ◽  
Vitelliform Macular Dystrophy ◽  
Best Vitelliform Macular Dystrophy

Best Vitelliform Macular Dystrophy (BVMD) is a phenocopy of North Carolina Macular Dystrophy (NCMD/MCDR1)

2021 ◽  
pp. 1-11
Author(s):  
Kent W. Small ◽  
Lee M. Jampol ◽  
Benjamin Bakall ◽  
Leslie Small ◽  
Robert Wiggins ◽  
...  
Keyword(s):  
North Carolina ◽  
Macular Dystrophy ◽  
Vitelliform Macular Dystrophy ◽  
Best Vitelliform Macular Dystrophy
Sign in / Sign up

Export Citation Format

Share Document